CagriSema vs Tirzepatide
Novo Nordisk's semaglutide plus cagrilintide combination versus Eli Lilly's GIP/GLP-1 dual agonist tirzepatide.
Last updated: January 28, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
CagriSema
Dossier overview
Tirzepatide
Dossier overview
Overview
CagriSema and tirzepatide represent different pharmaceutical strategies for enhanced weight loss. CagriSema combines two separate peptides (semaglutide and cagrilintide) into a single injection, while tirzepatide is a single molecule with dual receptor activity. Both aim to achieve greater efficacy than GLP-1 monotherapy.
This comparison is significant as it represents competition between the two major players in metabolic medicine: Novo Nordisk and Eli Lilly.
Key Facts
| Aspect | CagriSema | Tirzepatide |
|---|---|---|
| Developer | Novo Nordisk | Eli Lilly |
| Approach | Combination product | Single molecule |
| Targets | GLP-1 + Amylin | GIP + GLP-1 |
| FDA Status | Phase 3 (not approved) | FDA approved |
Mechanism Comparison
| Aspect | CagriSema | Tirzepatide |
|---|---|---|
| GLP-1 Activity | Semaglutide (agonist) | Built-in GLP-1 agonism |
| Second Mechanism | Cagrilintide (amylin analog) | GIP agonism |
| Receptor Targets | GLP-1R + AMY-R | GIPR + GLP-1R |
| Unique Feature | Amylin-based satiety | Novel dual agonist |
CagriSema Components
Semaglutide:
- GLP-1 receptor agonist
- Same as Wegovy/Ozempic
- Reduces appetite, slows gastric emptying
Cagrilintide:
- Long-acting amylin analog
- Enhances satiety signaling
- Slows gastric emptying (additive to GLP-1)
- Novel mechanism not previously combined with GLP-1
Tirzepatide Mechanism
- Single molecule with dual activity
- GIP receptor agonism (primary)
- GLP-1 receptor agonism (secondary)
- Synergistic effects on insulin and appetite
Clinical Trial Data
CagriSema Phase 3 (REDEFINE)
| Trial | Result |
|---|---|
| REDEFINE 1 | ~22.7% weight loss at 68 weeks |
| REDEFINE 2 (T2D) | Ongoing |
| REDEFINE Pivotal | Ongoing |
Note: Phase 3 data released in early 2024 showed strong results.
Tirzepatide Phase 3 (SURMOUNT)
| Trial | Dose | Weight Loss |
|---|---|---|
| SURMOUNT-1 | 15mg | -22.5% |
| SURMOUNT-2 | 15mg | -15.7% (T2D) |
| SURMOUNT-3 | 15mg | -26.6% (after lifestyle) |
| SURMOUNT-4 | 15mg | Maintained vs regain |
Efficacy Comparison
| Outcome | CagriSema | Tirzepatide |
|---|---|---|
| Max Weight Loss | ~22.7% (68 wk) | ~22.5% (72 wk) |
| ≥20% Weight Loss | ~55% | ~57% |
| ≥25% Weight Loss | ~35% | ~36% |
| HbA1c Reduction | TBD | -2.3% |
Important: These are cross-trial comparisons. Direct head-to-head data is not available.
Trial Population Differences
| Factor | REDEFINE 1 | SURMOUNT-1 |
|---|---|---|
| Baseline BMI | ~38 kg/m² | ~38 kg/m² |
| Duration | 68 weeks | 72 weeks |
| Background | No T2D | No T2D |
Side Effect Profile
Gastrointestinal Effects
| Side Effect | CagriSema | Tirzepatide |
|---|---|---|
| Nausea | ~40-45% | ~30-35% |
| Vomiting | ~20-25% | ~15-20% |
| Diarrhea | ~20% | ~20% |
| Constipation | ~15% | ~15% |
Note: CagriSema may have higher initial GI effects due to dual satiety mechanisms.
Discontinuation Rates
| Reason | CagriSema | Tirzepatide |
|---|---|---|
| GI Side Effects | ~6-8% | ~4-7% |
| Overall | ~10-12% | ~6-10% |
Unique Considerations
| Factor | CagriSema | Tirzepatide |
|---|---|---|
| Injection | Single combined | Single |
| Component Flexibility | Fixed ratio | N/A |
| Approved Components | Semaglutide (yes) | Tirzepatide (yes) |
| Amylin Experience | First long-acting combo | No amylin |
Regulatory and Development
| Aspect | CagriSema | Tirzepatide |
|---|---|---|
| Phase | Phase 3 ongoing | Approved |
| Expected Approval | 2025-2026 | Already approved |
| Obesity Approval | Pending | Yes (Zepbound) |
| T2D Approval | Pending | Yes (Mounjaro) |
Commercial Considerations
| Factor | CagriSema | Tirzepatide |
|---|---|---|
| First-mover | No | Yes |
| Brand Recognition | Builds on Wegovy | New brand |
| Manufacturing | Combination complexity | Single molecule |
| Pricing | Unknown | ~$1,000/month |
Evidence Quality
| Factor | CagriSema | Tirzepatide |
|---|---|---|
| Trial Phase | Phase 3 | Phase 3 complete |
| Sample Size | Thousands | Thousands |
| CV Outcomes | Pending | Ongoing (SURPASS-CVOT) |
| Real-World Data | None | Emerging |
| Long-term Safety | Limited | Growing |
Summary
| Factor | CagriSema | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 + Amylin | GIP + GLP-1 |
| Evidence Level | High (Phase 3) | High (approved) |
| Weight Loss | ~22.7% | ~22.5% |
| Unique Strength | Dual satiety pathways | Proven, available |
| Availability | Investigational | FDA approved |
Key Takeaways
- Similar efficacy: Both achieve approximately 22-23% weight loss in Phase 3 trials
- Different mechanisms: CagriSema adds amylin; tirzepatide adds GIP to GLP-1
- Tirzepatide is available: FDA-approved and commercially accessible
- CagriSema is promising: Strong Phase 3 data with novel amylin component
- No head-to-head trial: Cross-trial comparisons have limitations
- GI tolerance: Tirzepatide may have slightly better GI tolerability
- Choice will depend on: Availability, cost, insurance, individual response
This comparison is for educational purposes only. CagriSema is investigational and not approved. Consult a healthcare provider for treatment decisions.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.